1. Nattel S.The molecular and ionic specifity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol10:272-282.
2.
2. Singh BN, Vaughan Williams EM.A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol39:675-687.
3.
3. Singh BN, Vaughan Williams. The effect of amiodarone, a new antianginal drug, cardiac muscle. Br J Pharmacol39:657-667.
4.
4. Singh BN: Pharmacological Actions of Certain Cardiac Drugs and Hormones: Focus on Antiarrhythmic Mechanisms. DPhil Thesis, 1971; Hertford College & University of Oxford. England. Published also by Futura Publishing Co, Mt Kisco, NY pp 1-98, 1991.
5.
5. Vaughan Williams EM. Classification of antiarrhythmic drugs. E. Sandoe, E Flenstedt-Johnson, KH Olesen (eds): Symposium on Cardiac Arrhythmias. AB Astra, Sodertalje, Sweden, pp 440-469, 1970.
6.
6. Singh BN.A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res6:109-119.
7.
7. Singh BN, Hauswirth 0. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J87:367-382.
8.
8. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on Class III actions. Am J Cardiol84(9A): 11-19, 1999.
9.
9. Hauswirth 0, Singh BN. Ionic mechanisms in heart muscle in relationship to the genesis and the pharmacological control of cardiac arrhythmias. Pharmacol Rev30:5-63.
10.
10. Hondeghem LM, Snyders DJ. Class III anti-arrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use dependence. Circulation81:686-692.
11.
11. Dorian P, Newman D. Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: An overview. Europace2:277-285.
12.
12. Dorian P, Dunnman P, Elstun L, Newman D. The effect of isoproterenol on the Class III action azimilide in humans. J Cardiovasc Pharmacol Therapeut, 2002; this issue
13.
13. Chen F, Esmailian F, Sun W, Wetzel GT, Sarma JSM, Singh BN, Klitzner TS. Azimilide inhibits multiple cardiac potassium currents in human atrial myocytes. J Cardiovasc Pharmacol Therapeut, 2002; this issue
14.
14. Sun W, Sarma JSM, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: Comparison with amiodarone. J Cardiovasc Pharmacol39:677-684.
15.
15. Sager PT, Uppal P, Follmer CT, Antimisiaris M, Pruitt C, Singh BN. The frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation88: 1063-1068, 1993.
16.
16. Singh BN, Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol10:283-230.
17.
17. Camm AJ, Karam R, Pratt CM. The azimilide post-infarct survival evaluation (ALIVE) trial. Am Cardiol81:35D-39D, 1998
18.
18. Pritchett E, Page R, Connolly S, Marcello S. Azimilide treatment of atrial fibrillation. Circulation98(17)1-1:633-633 (Abstract), 1998.
19.
19. Singh BN, Sarma JSM. Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias. J Cardiovasc Pharmacol Therapeut1:69-87.
20.
20. Papp J Gy, Nemeth M, Krassoi I, Mester L, Hala 0, Varro A. Differential electro-physiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Pharmacol Exp Therapeut1(4):187-196, 1996.
21.
21. Sicouri S, Moro S, Litovsky S, Elizari M, Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol8:1269-1276.
22.
22. Cui G, Sen L, Sager PT, Uppal P, Singh BN. Effects of amiodarone, sematilide and sotalol on QT dispersion. Am J Cardiol75:465-469.
23.
23. Wang Z, Pelletier LC, Talajic M, Nattel S. Effects of flecainide and quinidine on human atrial potentials: Role of rate dependence and comparison with guinea pig, rabbit and dog tissues. Circulation82:274-283.